Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A 32-Week Evaluation.
Özden Ş +8 more
europepmc +1 more source
Analysis of Selected Serum Cytokines to Evaluate the Early Efficacy of Benralizumab, Dupilumab, and Mepolizumab in Severe Eosinophilic Asthma Treatment. [PDF]
Niemiec-Górska A +8 more
europepmc +1 more source
Cytokine and Metabolomic Signatures of Mepolizumab Response Across Upper and Lower Airway Compartments in Severe Eosinophilic Asthma: An Exploratory Analysis. [PDF]
Maniscalco M +8 more
europepmc +1 more source
Population Pharmacokinetics and Exposure-Response Analysis of Benralizumab in Chinese Adults, Adolescents, and Pediatric Participants with Severe Eosinophilic Asthma. [PDF]
Jin Y +9 more
europepmc +1 more source
DUPILUMAB-INDUCED EOSINOPHILIC PLEURAL EFFUSION IN A PATIENT WITH SEVERE ASTHMA: A CASE REPORT [PDF]
MOHAMMAD FREIHAT +3 more
openalex +1 more source
Benralizumab and the integrated management of co-morbid severe eosinophilic asthma with chronic rhinosinusitis with nasal polyps. [PDF]
Mullol J +4 more
europepmc +1 more source
Responses to Biological Therapy in Severe Eosinophilic Asthma
M J Alvarez-Puebla +5 more
openalex +1 more source
Effects of azithromycin in severe eosinophilic asthma with concomitant monoclonal antibody treatment. [PDF]
Lavoie G +11 more
europepmc +1 more source
Early and Sustained Clinical Benefits of Benralizumab in Severe Eosinophilic Asthma: Findings from the ORBE II Study. [PDF]
Ausín P +8 more
europepmc +1 more source

